Table 3.
Resource use and health state costs
| Parameter | Weekly cost | Source |
|---|---|---|
| Health states | ||
| No ulcer | £5.21 | [4] |
| Uninfected ulcer | £463 | [4] |
| Infected ulcer | £460 | [4] |
| Amputation | £818 | [4] |
| d-Nav Service | ||
| Installation fee | £102.17 | Communication with service provider |
| Service fee | ||
| 0–50 users | £44.96 | Communication with service provider |
| 51–100 users | £40.46 | Communication with service provider |
| 101–200 users | £36.67 | Communication with service provider |
| >200 users | £33.72 | Communication with service provider |
| Anti-diabetic drugs | ||
| Metformin | £0.25 | [31] |
| Sitagliptin | £9.83 | [31] |
| Saxagliptin | £8.80 | [31] |
| Linagliptin | £8.75 | [31] |
| Vildagliptin | £7.63 | [31] |
| Pioglitazone | £3.88 | [31] |
| Dapagliflozin | £10.39 | [31] |
| Liraglutide | £15.36 | [31] |
| Exenatide | £20.31 | [31] |
| Acarbose | £2.19 | [31] |
| Repaglinide | £3.53 | [31] |
| Nateglinide | £6.69 | [31] |
| Metformin/Pioglitazone | £10.65 | [31] |
| Metformin/Vildagliptin | £9.64 | [31] |
| Metformin/Sitagliptin | £10.26 | [31] |
| Metformin/Linagliptin | £9.52 | [31] |
| Insulin regimens | ||
| Lantus® (long-acting) | £30.68 per 1000 units | [30] |
| Apidra® (short-acting) | £16.00 per 1000 units | [30] |
| Humulin M3® (biphasic) | £15.68 per 1000 units | [30] |
| Blood glucose monitoring | £6.84 | [24, 25] |
All costs that have been applied within the analysis are summarized in the table, with the original source also given. All costs are weekly and per patient